By Karen Roman
Oncology-focused biotech company SkylineDx said an independent study shows that Merlin CP-GEP, the company’s test for treatment decisions in early-stage melanoma, correctly categorizes patients with skin melanoma for sentinel lymph node biopsy (SLNB).
Merlin acts as a deselection tool for SLNB and lets professionals distinguish patients that can avoid this invasive surgical procedure and its potentials complications, the company stated.
“It is really exciting to see that the robust and consistent performance of our Merlin Assay has been confirmed independently by this work,” said Jvalini Dwarkasing, PhD, SkylineDx Chief Scientific Officer. “These findings further validate its clinical utility as a precision medicine tool to guide more informed decisions around sentinel lymph node biopsies in melanoma patients.”
READ MORE FROM HEALTHCARE EDGE
Nanox Collaborates with Keiser University for 3D Imaging System & Training
Register for our weekly newsletter HERE
Contact:
Click HERE to follow us on LinkedIn
